CTRI/2011/04/001682已完成2 期
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
ovartis Healthcare Pvt Ltd0 个研究点目标入组 910 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 910
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Severe hypertension
- •2. Written informed consent must be obtained before any assessment is performed. Patients with mild-to-moderate systolic hypertension, untreated or currently taking antihypertensive therapy.
- •3. Ability to communicate and comply with all study requirements and demonstrate good medication compliance ( greater than or equal to 80 percent compliance rate) during the run-in period.
排除标准
- •1. History of angioedema, drug-related or otherwise, as reported by the patient.
- •2. Pregnant or nursing (lactating) women.
- •3. Women of child-bearing potential (WOCBP), UNLESS they are using adequate birth control methods.
- •4. History or evidence of a secondary form of hypertension.
- •5. Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing - M10-261, FINAL 30Nov07MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-005905-23-GBAbbott GmbH & Co. KG424
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo - controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week DosingRheumatoid ArthritisEUCTR2007-005905-23-DEAbbott GmbH & Co. KG424
暂停
3 期
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- AntihistaminesChronic Inducible UrticariaCINDUCINDLBCTR2022014919ovartis Pharmaceuticals8
进行中（未招募）
1 期
To assess the efficacy of NTRA-2112 on intestinal malabsorption due to gastro-intestinal immaturity by measuring the time required to reach full enteral feeding in preterm infants during the treatment period compared to a placebo formulation.Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants.MedDRA version: 20.1Level: LLTClassification code 10025479Term: Malabsorption syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: PTClassification code 10025476Term: MalabsorptionSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-002624-28-FRutrinia300
进行中（未招募）
不适用
Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary NailingAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10043827Term: Tibia fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-DEAmgen Inc400